The Medicines and Healthcare products Regulatory Agency (MHRA) has announced a £1 million funding boost for its AI Airlock programme, designed to provide a unique regulatory testing environment where companies can collaborate directly with regulators to safely trial new AI-powered medical devices. This initiative aims to accelerate patient access to innovative technologies by streamlining regulatory pathways.
Following a successful pilot phase involving four breakthrough AI tools—including software for personalised cancer treatment planning and a real-time AI performance monitoring system—the second round of applications opened on June 23, 2025. The AI Airlock creates a regulatory “sandbox” that separates experimental AI from fully approved medical technologies used clinically, enabling safe innovation.
This programme aligns with the UK Government’s AI Opportunities Action Plan and the Regulatory Horizons Council’s recommendations, enhancing regulators’ ability to oversee AI in healthcare. Science Minister Lord Vallance highlighted that initiatives like the AI Airlock help reduce bureaucracy and bring safe technologies to patients faster, supporting the NHS and the Government’s Plan for Change. Health Minister Baroness Merron emphasized the importance of safely harnessing AI’s potential while maintaining rapid development.
To qualify for the second funding cohort, applicants must demonstrate significant potential benefits to patients and the NHS, present novel treatment approaches, and face regulatory challenges suitable for the Airlock environment. Applications are open until July 14, 2025. More details are available on the GOV.UK website.
Follow MEDWIRE.AI for updates on AI and MedTech innovation.
